Cynthia
UKC Forum Member
Registered: Jun 2003
Location: North Carolina
Posts: 4502 |
according to the product label, comfortis was tested. its states to use caution. also note that the test group was given way over the recommended dosages.
Animal Safety:
COMFORTIS chewable tablets were tested in pure and mixed breeds of healthy dogs in well-controlled clinical
and laboratory studies. No dogs were withdrawn from the field studies due to treatment-related adverse reactions.
In a dose tolerance study, COMFORTIS chewable tablets were administered orally to adult Beagle dogs at
average doses of up to 100 mg/kg once daily for 10 consecutive days (16.7 times the maximum recommended monthly dose). Vomiting was seen in 5 of 6 treated dogs during the first 6 days of treatment, usually within 2.5
hours of dosing. Treated females lost weight early in the treatment period, but their weights were similar to control
dogs by the end of the 24-day study. COMFORTIS chewable tablets were not associated with any clinically
significant changes in hematology, blood coagulation or urinalysis parameters; however, mild elevations in ALT
occurred in all dogs treated with COMFORTIS chewable tablets. By day 24, ALT values had returned to near
baseline levels. Phospholipidosis (vacuolation) of the lymphoid tissue was seen in all dogs treated with
COMFORTIS chewable tablets, the long-term effects of which are unknown.
In a margin of safety study, COMFORTIS chewable tablets were administered orally to 6-week-old Beagle
puppies at average doses of 1.5, 4.4, and 7.4 times the maximum recommended dose at 28-day intervals over a
6-month period. Vomiting was observed across all groups, including the control. Increased vomiting was observed
at elevated doses, usually within 1 hour following administration. Vomiting at all doses decreased over time and
stabilized when puppies were 14 weeks of age. The average daily and total weight gains of treated dogs were
smaller than control dogs and were dose dependent. COMFORTIS chewable tablets were not associated with
clinically significant changes in hematology, clinical chemistry, coagulation or urinalysis parameters.
Phospholipidosis (vacuolation) of the lymphoid tissue was seen in some dogs in the 4.4X group and all dogs in the
7.4X group. The long term effects of phospholipidosis are unknown. Treatment with COMFORTIS chewable
tablets was not associated with any other clinically significant adverse clinical observations, gross necropsy or
histopathological changes.
In a reproductive safety study, COMFORTIS chewable tablets were administered orally to female Beagles at 1.3
and 4.4 times the maximum recommended therapeutic dose every 28 days prior to mating, during gestation, and
during a six-week lactation period. No treatment-related adverse effects were noted for conception rates in the
dams, or for mortality, body temperature, necropsy, or histopathology findings for the dams or puppies. One dam
from each treatment group experienced early pregnancy loss and one additional high dose dam aborted late term.
The treated dams experienced more vomiting, especially at one hour post-dose, than the control dams. Puppies
from dams treated at 1.3 times the maximum recommended therapeutic dose had lower body weights than
puppies from control dams. Although puppy mortality between treated and control dams was not different, the
puppies from the treated dams experienced more lethargy (4.4X group only), dehydration, weakness and felt cold
to the touch (4.4X group only) than puppies from control dams.
A pilot study without a control group was conducted to analyze milk from three lactating dogs treated with an
experimental formulation of spinosad at 1.5 times the maximum recommended dose administered at day 28 of
gestation and 24 hours prior to parturition. The data demonstrated that spinosyns were excreted in the milk of
these dogs. Mortality and morbidity were greatest in puppies from the dam with the highest spinosyns level in milk.
The spinosad milk: reference plasma exposure ratio calculated from this study ranged from 2.2 to 3.5.
In well-controlled field studies, COMFORTIS chewable tablets were administered safely in conjunction with other
frequently used veterinary products, such as vaccines, anthelmintics, antibiotics, steroids, flea and tick control
products, anesthetics, NSAIDs, antihistamines, alternative/herbal remedies, shampoos, and prescription diets.
Changes in hematology, clinical chemistry and urinalysis values were compared pre-and post-study and were
unremarkable.
__________________
2012 National Grand Show Champion, World Show Bluetick Female CCH GRCH 'PR' Southern Flame Blame it on the Rain (Rain)
2012 Purina Show Bluetick Breed Winner GRCH 'PR' Southern Flame Grt Balls o' Fire (Jerry Lee)
2013 World Champion Bluetick, 2013 AO Overall Bred By winner GRCH 'PR' Sexy and I know It (breeder)
2015 AO Overall Dual Champion NTCH GRCH 'PR' Sexy and I know It (breeder/owner/handler)
2016 Grand American Overall Dual Ch, Overall Show CHampion NTCH GRCH 'PR' Sexy and I know It
AKC CSG, UKC CCH GRCH 'PR' Southern Flame Bad News Bandit (Bandit)
2010 National Grand Champion Bluetick
2013 AO Bluetick Stud Dog winner
CCH GCH 'PR' Southern Flame Elvira - the one that started it all
southernflamekennel@earthlink.net
RIP Southern Flame Elvira (the cornerstone of the kennel) 5/16/02-1/17/14
RIP Southern Flame Scarlet (the lone Redbone) 5/11/01-7/19/13
RIP Southern Flame Wild Irish Rose (Rosie) 6/15/09 - 3/12/15
RIP Southern Flame Too Hot to Trot (Bonnie) 3/27/07 - 4/20/15
RIP Southern Flame Bad News Bandit (Bandit)
RIP Southern Flame Triple Trouble (TT) 12/17/04 - 11/19/16
RIP Southern Flame Blame it on the Rain (Rain)
RIP AdeleMay's a Smokey Bandit (Adele)
RIP Southern Flame I Like Ike (Ike)
RIP Bella the Beagle
Bear, Jerry Lee, Camo, Maybellene, Lacy, Thor, Sissy, Merle, Tina, Bridgette - the Blueticks, Hollie - the Aussie
Report this post to a moderator | IP: Logged
|